Novo Nordisk AS (NVO)
105.40
-1.51
(-1.41%)
USD |
NYSE |
Nov 14, 16:00
105.06
-0.34
(-0.32%)
After-Hours: 20:00
Novo Nordisk Research and Development Expense (Quarterly): 1.398B for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.398B |
| June 30, 2024 | 2.333B |
| March 31, 2024 | 1.254B |
| December 31, 2023 | 1.510B |
| September 30, 2023 | 1.187B |
| June 30, 2023 | 1.042B |
| March 31, 2023 | 970.27M |
| December 31, 2022 | 1.111B |
| September 30, 2022 | 762.61M |
| June 30, 2022 | 733.41M |
| March 31, 2022 | 785.33M |
| December 31, 2021 | 866.26M |
| September 30, 2021 | 674.11M |
| June 30, 2021 | 639.17M |
| March 31, 2021 | 639.35M |
| December 31, 2020 | 718.12M |
| September 30, 2020 | 614.39M |
| June 30, 2020 | 486.02M |
| March 31, 2020 | 557.60M |
| December 31, 2019 | 649.91M |
| September 30, 2019 | 536.43M |
| June 30, 2019 | 535.14M |
| March 31, 2019 | 407.57M |
| December 31, 2018 | 694.69M |
| September 30, 2018 | 568.25M |
| Date | Value |
|---|---|
| June 30, 2018 | 528.13M |
| March 31, 2018 | 547.88M |
| December 31, 2017 | 630.23M |
| September 30, 2017 | 525.94M |
| June 30, 2017 | 504.80M |
| March 31, 2017 | 471.18M |
| December 31, 2016 | 648.16M |
| September 30, 2016 | 518.52M |
| June 30, 2016 | 505.69M |
| March 31, 2016 | 488.49M |
| December 31, 2015 | 591.57M |
| September 30, 2015 | 489.80M |
| June 30, 2015 | 449.39M |
| March 31, 2015 | 492.25M |
| December 31, 2014 | 648.56M |
| September 30, 2014 | 649.75M |
| June 30, 2014 | 565.08M |
| March 31, 2014 | 581.56M |
| December 31, 2013 | 650.72M |
| September 30, 2013 | 496.71M |
| June 30, 2013 | 475.60M |
| March 31, 2013 | 470.21M |
| December 31, 2012 | 558.17M |
| September 30, 2012 | 439.34M |
| June 30, 2012 | 442.56M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
486.02M
Minimum
Jun 2020
2.333B
Maximum
Jun 2024
946.57M
Average
773.97M
Median
Research and Development Expense (Quarterly) Benchmarks
| Ascendis Pharma AS | 89.88M |
| Amgen Inc | 1.45B |
| AstraZeneca PLC | 3.008B |
| Grifols SA | 96.65M |
| Viking Therapeutics Inc | 22.78M |